Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929918 | 0.86 | KDM4E (0.55) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2523027 | 0.84 | KDM4E (0.53) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2521606 | 0.84 | SMN1; SMN2 (0.53) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27819764 | 0.83 | EP300 (0.55) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2228797 | 0.82 | KDM4E (0.61) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2353928 | 0.80 | KDM4E (0.58) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3771486 | 0.80 | PARP14 (0.54) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11729407 | 0.80 | KDM4E (0.49) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4263785 | 0.79 | ALDH1A1 (0.61) | POLBRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2229406 | 0.79 | KDM4E (0.51) | KDM4EPOLBRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397257-A1 | COMPOSITIONS AND NETHODS FOR TREATING BRAIN DYSFUNCTION | Bach Pharma, Inc. (US) | 2018-11-07 | — | — | EP | claimed |
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | claimed |
| WO-2017117586-A1 | COMPOSITIONS AND NETHODS FOR TREATING BRAIN DYSFUNCTION | BACH PHARMA, INC. (US) | 2017-07-06 | — | — | WO | claimed |
| US-20140030317-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Occhiuti & Rohlicek LLP | 2014-01-30 | — | — | US | claimed |
| EP-2398325-A1 | METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS | Bach Pharma, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2346522-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS | Bach Pharma, Inc. (US) | 2011-07-27 | — | — | EP | claimed |
| US-20100255077-A1 | METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS | BACH PHARMA, INC. (US) | 2010-10-07 | — | — | US | claimed |
| WO-2010096686-A1 | METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS | BACH PHARMA, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20100086531-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND Nrf2 TRANSCRIPTION FACTORS | BACH PHARMA INC. (US) | 2010-04-08 | — | — | US | claimed |
| US-7691819-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2010-04-06 | — | — | US | claimed |
| WO-2010036711-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS | BACH PHARMA INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20090036411-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. (US) | 2009-02-05 | — | — | US | claimed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | claimed |
| US-20050288291-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2005-12-29 | — | — | US | claimed |
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2018129171-A1 | ENZYMATICALLY ACTIVATABLE PEPTIDE-REDOX MODULATOR CONJUGATES AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007018546-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20050288291-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | GPX1, GPX4, ENPEP | KDM4E 3286/4885POLB 2945/4885RAB9A 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.